↓ Skip to main content

Dual Influence of Endocannabinoids on Long-Term Potentiation of Synaptic Transmission

Overview of attention for article published in Frontiers in Pharmacology, December 2017
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Good Attention Score compared to outputs of the same age and source (72nd percentile)

Mentioned by

twitter
3 X users
reddit
1 Redditor

Citations

dimensions_citation
27 Dimensions

Readers on

mendeley
80 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Dual Influence of Endocannabinoids on Long-Term Potentiation of Synaptic Transmission
Published in
Frontiers in Pharmacology, December 2017
DOI 10.3389/fphar.2017.00921
Pubmed ID
Authors

Armando Silva-Cruz, Mattias Carlström, Joaquim A. Ribeiro, Ana M. Sebastião

Abstract

Cannabinoid receptor 1 (CB1R) is widely distributed in the central nervous system, in excitatory and inhibitory neurons, and in astrocytes. CB1R agonists impair cognition and prevent long-term potentiation (LTP) of synaptic transmission, but the influence of endogenously formed cannabinoids (eCBs) on hippocampal LTP remains ambiguous. Based on the knowledge that eCBs are released upon high frequency neuronal firing, we hypothesized that the influence of eCBs upon LTP could change according to the paradigm of LTP induction. We thus tested the influence of eCBs on hippocampal LTP using two θ-burst protocols that induce either a weak or a strong LTP. LTP induced by a weak-θ-burst protocol is facilitated while preventing the endogenous activation of CB1Rs. In contrast, the same procedures lead to inhibition of LTP induced by the strong-θ-burst protocol, suggestive of a facilitatory action of eCBs upon strong LTP. Accordingly, an inhibitor of the metabolism of the predominant eCB in the hippocampus, 2-arachidonoyl-glycerol (2-AG), facilitates strong LTP. The facilitatory action of endogenous CB1R activation does not require the activity of inhibitory A1 adenosine receptors, is not affected by inhibition of astrocytic metabolism, but involves inhibitory GABAergic transmission. The continuous activation of CB1Rs via exogenous cannabinoids, or by drugs known to prevent metabolism of the non-prevalent hippocampal eCB, anandamide, inhibited LTP. We conclude that endogenous activation of CB1Rs by physiologically formed eCBs exerts a fine-tune homeostatic control of LTP in the hippocampus, acting as a high-pass filter, therefore likely reducing the signal-to-noise ratio of synaptic strengthening.

X Demographics

X Demographics

The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 80 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 80 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 21 26%
Student > Bachelor 11 14%
Student > Master 7 9%
Student > Doctoral Student 5 6%
Researcher 5 6%
Other 10 13%
Unknown 21 26%
Readers by discipline Count As %
Neuroscience 21 26%
Agricultural and Biological Sciences 14 18%
Pharmacology, Toxicology and Pharmaceutical Science 6 8%
Biochemistry, Genetics and Molecular Biology 4 5%
Medicine and Dentistry 3 4%
Other 5 6%
Unknown 27 34%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 January 2018.
All research outputs
#13,474,983
of 23,011,300 outputs
Outputs from Frontiers in Pharmacology
#4,042
of 16,316 outputs
Outputs of similar age
#215,903
of 440,391 outputs
Outputs of similar age from Frontiers in Pharmacology
#73
of 263 outputs
Altmetric has tracked 23,011,300 research outputs across all sources so far. This one is in the 41st percentile – i.e., 41% of other outputs scored the same or lower than it.
So far Altmetric has tracked 16,316 research outputs from this source. They receive a mean Attention Score of 5.0. This one has done well, scoring higher than 75% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 440,391 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 50% of its contemporaries.
We're also able to compare this research output to 263 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 72% of its contemporaries.